INT200462

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2003
Last Reported 2008
Negated 1
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 4.95
Pain Relevance 1.00

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lysosome (IDS)
Anatomy Link Frequency
muscle 1
IDS (Homo sapiens)
Pain Link Frequency Relevance Heat
Angina 259 96.00 Very High Very High Very High
Antihistamine 8 83.12 Quite High
imagery 130 71.88 Quite High
tolerance 32 70.32 Quite High
Central nervous system 13 60.96 Quite High
depression 22 26.04 Quite Low
Pain 60 13.12 Low Low
adenocard 18 5.00 Very Low Very Low Very Low
Inflammation 12 5.00 Very Low Very Low Very Low
Substantia nigra 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 258 99.64 Very High Very High Very High
Mucopolysaccharidoses 7 99.32 Very High Very High Very High
Myocardial Infarction 146 99.16 Very High Very High Very High
Fabry Disease 1 98.24 Very High Very High Very High
Gauchers Disease 3 97.64 Very High Very High Very High
Diabetes Mellitus 76 97.44 Very High Very High Very High
Aging 16 97.00 Very High Very High Very High
Stress 213 96.84 Very High Very High Very High
Frailty 6 96.48 Very High Very High Very High
Angina 169 96.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Current treatment with idursulfase
idursulfase Binding (treatment) of
1) Confidence 0.31 Published 2007 Journal Eur J Pediatr Section Body Doc Link PMC2234442 Disease Relevance 0 Pain Relevance 0.04
MPS activity in the UK
MPS Binding (activity) of
2) Confidence 0.23 Published 2003 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC2562441 Disease Relevance 0.17 Pain Relevance 0.12
American guidelines recommend MPS for risk stratification in low-risk patients following STEMI (Table 16).
MPS Binding (recommend) of
3) Confidence 0.20 Published 2003 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC2562441 Disease Relevance 0.62 Pain Relevance 0.14
Evidence from modelling and observational studies supports the enhanced cost-effectiveness associated with MPS use.
MPS Binding (associated) of
4) Confidence 0.20 Published 2003 Journal Eur J Nucl Med Mol Imaging Section Abstract Doc Link PMC2562441 Disease Relevance 0.71 Pain Relevance 0.34
MPS as the gatekeeper to angiography
MPS Binding (gatekeeper) of
5) Confidence 0.20 Published 2003 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC2562441 Disease Relevance 0.47 Pain Relevance 0.10
Recent UK guidelines recommend MPS in stabilised patients who cannot exercise [278].
MPS Binding (recommend) of
6) Confidence 0.20 Published 2003 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC2562441 Disease Relevance 0.58 Pain Relevance 0.11
In a study of 1,371 patients, normal MPS was associated with an incidence of cardiovascular events of 1–2% per year, while the incidence was greater than 7% per year in those with severe perfusion abnormalities [184].
MPS Binding (associated) of associated with congenital anomalies
7) Confidence 0.20 Published 2003 Journal Eur J Nucl Med Mol Imaging Section Body Doc Link PMC2562441 Disease Relevance 1.46 Pain Relevance 0.07
Recombinant iduronate-2-sulfatase (idursulfase, Elaprase®; Shire HGT Pharmaceuticals, Cambridge, MA, USA) was approved in July, 2006 in the US and January, 2007 in Europe as a safe and effective treatment for individuals with MPS II.
idursulfase Binding (Recombinant) of
8) Confidence 0.16 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721351 Disease Relevance 0.43 Pain Relevance 0.08
We believe that this discrepancy is because of the biomechanical interaction among the shoes, MPs and feet when using insole measurement.
MPs Binding (interaction) of
9) Confidence 0.12 Published 2006 Journal BMC Musculoskelet Disord Section Body Doc Link PMC1712337 Disease Relevance 0 Pain Relevance 0
The statistically most significant overlap (Fisher Exact test) between the 892 priority genes and GO groups was found for GO ID 0016020 (membrane) and GO IDs 0005515/0045308 (protein binding or protein degradation tagging activity, respectively).
IDs Binding (binding) of
10) Confidence 0.12 Published 2008 Journal Neurogenetics Section Body Doc Link PMC2238789 Disease Relevance 0.14 Pain Relevance 0
However, the barefoot measurement may not reflect the actual biomechanical effect after MP placement in the daily life, since the interaction among MPs, feet and shoes cannot be studied.
MPs Binding (interaction) of
11) Confidence 0.09 Published 2006 Journal BMC Musculoskelet Disord Section Body Doc Link PMC1712337 Disease Relevance 0 Pain Relevance 0
Additional quality control procedures include: (1) randomly selected comparison of data points between the paper records and the electronic records in the SQL database at each study site, and (2) frequency distributions checks of key outcome variables (overall, not stratified by treatment assignment) along with a list of participant IDs associated with possible outliers or questionable data points.
IDs Binding (associated) of
12) Confidence 0.05 Published 2007 Journal BMC Neurol Section Body Doc Link PMC2222229 Disease Relevance 0 Pain Relevance 0
There is no data available for diurmal variation in human muscle MPS but we suggest that the basal, postabsorptive rate, which was ?
MPS Neg (no) Binding (variation) of in muscle
13) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2267222 Disease Relevance 0.38 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox